S54
Brachytherapy - Gynaecology
ESTRO 2026
1 Department of Radiation Oncology, Benavides Cancer Institute, University of Santo Tomas Hospital, Manila, Philippines. 2 Department of Gynecologic Oncology, Manila Doctors Hospital, Manila, Philippines. 3 Department of Obstetrics and Gynecology, Allied Care Experts Malolos Doctors, Bulacan, Philippines. 4 Department of Obstetrics and Gynecology, De Los Santos Medical Center, Manila, Philippines. 5 Department of Gynecologic Oncology, University of Santo Tomas Hospital, Manila, Philippines. 6 Department of Radiation Oncology, Manila Doctors Hospital, Manila, Philippines Purpose/Objective: External beam radiotherapy (EBRT) with concurrent chemotherapy followed by brachytherapy remains the standard of care for locally advanced cervical cancer. For bulky or asymmetric tumors with parametrial, vaginal, or bladder/rectal involvement, interstitial brachytherapy (ISBT) is used to optimize dose coverage.1 In patients unfit for ISBT, EBRT boost with ICBT has historically been used as an alternative.2 However, evidence directly comparing outcomes between EBRT boost + ICBT and ISBT remains limited. We report our outcomes with sequential adaptive EBRT boost + ICBT, benchmarked against ISBT. Material/Methods: This retrospective multi-institutional study included patients with FIGO 2021 stage IIIA, IIIB, IIIC with IIIA/B primary extensions, and IVA cervical cancer treated between 2019 and 2025. All patients received IMRT- based EBRT, followed by either adaptive EBRT boost and ICBT, or ISBT. Primary outcomes were overall survival (OS) and progression-free survival (PFS), and secondary outcomes included acute and late toxicity. Survival analyses used the Kaplan-Meier method, and prognostic factors were explored with univariate log- rank tests and multivariate Cox proportional hazards
Conclusion: This study demonstrates that this type of audit is a valuable tool for assessing the quality indicators of the given treatments. It can support quality improvement initiatives and serve as a baseline when implementing future changes to the patient workflow, such as modifications in dose planning methods, EQD2 dose planning aims, process or structural changes and also for evaluating the overall management of cervical cancer. Keywords: Cervical Cancer, quality indicators, audit References: [1 ]Chargari C, Tanderup K, Planchamp F et al: ESGO/ESTRO quality indicators for radiation therapy of cervical cancer, Radiotherapy and Oncology 183 (2023) 109589[2] Tanderup K, Nesvacil N, Kircheiner K et al: Evidence-based dose planning aims and dose prescription, Semin Radiotherapy and Oncology 30 (2020) 311-327[3] Mohamed S, Lindegaard JC, De Leeuw AAC et al: Vaginal dose de- escalation in image guided adaptive brachytherapy for locally advanced cervical cancer, Radiotherapy and Oncology 120 (2016) 480-485 Digital Poster 1511 External Beam Radiotherapy Boost with Intracavitary Brachytherapy Versus Interstitial Brachytherapy in Cervical Cancer: A Multi- Institution Experience Vannesza Hendricke C. Chua 1 , Carl Jay E. Jainar 1 , Patricia J. Ong 1 , Leona Marie Francesca S. Rebosa 1 , Bryce Matthew L. Tan De Guzman 1 , Patricia Ann A. Ferolin 2 , Jayson L. Co 1 , Renee Riza C. Medalla 3 , Irene M. Tagayuna 4 , Aida J. Bautista 2 , Jocelyn Z. Mariano 5 , Warren R. Bacorro 1,6
models. Results:
A total of 48 patients were included (29 ISBT; 19 EBRT boost + ICBT) with a median follow-up of 9.5 months. Median OS was not reached in either group.
Table 1. Baseline characteristicsEstimated 1-year OS was 86.9% vs 63.8% (p=0.45), and 1-year PFS was
Made with FlippingBook - Share PDF online